In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers

  • Y. S. R. Krishnaiah
  • V. Satyanarayana
  • B. Dinesh Kumar
  • R. S. Karthikeyan
  • P. Bhaskar


The present study involved the in vivo evaluation of orally administered guar gum-based colon-targeted tablet formulations of celecoxib (colon-targeted tablet-20 or colon-targeted tablet-30) as compared with an immediate release capsule in 15 human volunteers. Blood samples were obtained at different time intervals and the plasma concentration of celecoxib was estimated by reversed phase HPLC. The immediate release capsules of celecoxib might have disintegrated very fast in GI tract and absorbed quickly from stomach and small intestine thereby producing peak plasma concentration (Cmax of 478±57 ng/ml) within 3.8±0.1 h (Tmax). Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8h resulting in peak concentration (Cmax) of 78±6ng/ml or 88±15ng/ml at 10.5±1.9 h or 13.5±1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478±57 ng/ml at 3.8±0.1h (Tmax). Colon-targeted tablets showed decreased AUC0–∞, Cmax and absorption rate constant, prolonged absorption time (ta), and increased t1/2 in comparison with the immediate release capsules. The results of the study indicated that the guar gum-based colon-targeted tablets of celecoxib did not release the drug significantly in stomach and small intestine, but delivered to the colon resulting in a slow absorption of the drug and making it available for local action in the colon.


Celecoxib Colon-targeted tablets Guar gum In vivo evaluation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kudo T., Narisawa T., Abo S. (1980): Anti-tumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann., 71, 260–264.PubMedGoogle Scholar
  2. 2.
    Oshima M., Dinchuk J.E., Kargman S.L. (1996): Suppression of intestinal polysis in Ape delta 716 knock out mice by inhibition of cyclooxygenase-2 (COX-2). Cell., 87, 803–809.CrossRefPubMedGoogle Scholar
  3. 3.
    Kawamori T., Rao C.V., Seibert K., Reddy B.S. (1998): Chemoprotective activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409–412.PubMedGoogle Scholar
  4. 4.
    Kalgutkar A.S., Crews B.C., Rowlinson S.W. (1998): Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science., 280, 1268–1270.CrossRefPubMedGoogle Scholar
  5. 5.
    Janne P.A., Mayer R.J. (2000): Primary care: Chemoprevention of colorectal cancer. N. Engl. J Med., 342, 1960–1968.CrossRefPubMedGoogle Scholar
  6. 6.
    Steinbach G., Lynch P.M., Phillips R.K.S. et al. (2000): The Effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946–1952.CrossRefPubMedGoogle Scholar
  7. 7.
    Reddy B.S., Hirose Y., Lubet R., Steele V. et al. (2000): Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis. Cancer Res., 60, 293–297.PubMedGoogle Scholar
  8. 8.
    Needleman P., Isakson P.C. (1998): Selective inhibition of cyclooxygenase-2. Science and Medicine., 1, 26–35.Google Scholar
  9. 9.
    Krishnaiah Y.S.R., Satyanarayana V., B Dinesh Kumar. et al. (2002): Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J. Drug Target., 10, 247–254.CrossRefPubMedGoogle Scholar
  10. 10.
    Rama Prasad Y. V., Krishnaiah Y.S.R., S. Satyanarayana. (1998): In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J. Control. Rel., 51, 281–287CrossRefGoogle Scholar
  11. 11.
    Gibaldi M., Perrier, D. (1990): Pharmacokinetics, 2nd edition, Marcel Dekker, New York.Google Scholar
  12. 12.
    Ritschel W.A. (1986): UC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis. Methods and findings of Experimental Clinical Pharmacology. 8: 633–640.Google Scholar
  13. 13.
    Krishnaiah Y.S.R., Satyanarayana S., Rama Prasad Y.V. et al. (1998): Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy subjects. J. Control. Rel., 55, 245–252.CrossRefGoogle Scholar
  14. 14.
    Krishnaiah Y.S.R., Satyanarayana S Rama Prasad Y.V. et al. (1998): Evaluation of guar gum as a compression coat for drug targeting to colon. Int. J. Pharm., 171, 137–146.CrossRefGoogle Scholar
  15. 15.
    Krishnaiah Y.S.R., Satyanarayana S., Rama Prasad Y.V. et al. (1999): Studies on guar gum compression coated 5-amino salicylic acid tablets for Colon-specific drug delivery. Drug Dev. Ind. Pharm., 25, 651–657.CrossRefPubMedGoogle Scholar
  16. 16.
    Krishanaiah Y.S.R., Veer Raju P., Dinesh Kumar B. et al. (2001): Development of colon targeted drug delivery systems for mebendazole. J. Control. Rel., 77, 87–95.CrossRefGoogle Scholar
  17. 17.
    Krishnaiah Y.S.R., Bhaskar Reddy P.R., Satyanarayana V. et al. (2002): Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int. J. Pharm., 236, 43–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Krishnaiah Y.S.R., Satyanarayana V., Dinesh Kumar B. et al. (2002): In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur. J. Pharm. Sci., 16, 185–192.CrossRefPubMedGoogle Scholar
  19. 19.
    Krishnaiah Y.S.R., Indira Muzib Y., Srinivasa Rao G. et al. (2002). Design and In vitro evaluation of oral colon targeted drug delivery systems for tinidazole. J. Drug Target., (accepted).Google Scholar
  20. 20.
    Grahnen A. (1984): Design of bioavailability studies. Pharm. Int., 5, 100–103.Google Scholar
  21. 21.
    Westlake W.J. (1988) In: K.E. Peace (ed.), Biopharmaceutical statistics for drug development, Marcel Dekker, New York, 329.Google Scholar
  22. 22.
    RobertsII L.J., Morrow J.D. (2001): Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics (10th edition), McGraw Hill, Medical Publishing Division, New York, 715.Google Scholar

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Y. S. R. Krishnaiah
    • 1
  • V. Satyanarayana
    • 2
  • B. Dinesh Kumar
    • 1
  • R. S. Karthikeyan
    • 2
  • P. Bhaskar
    • 2
  1. 1.National Institute of NutritionHyderabadIndia
  2. 2.Department of Pharmaceutical SciencesAndhra UniversityVisakhapatnamINDIA

Personalised recommendations